Safety profile of ipilimumab in elderly patients: a disproportionate analysis based on the FDA Adverse Event Reporting System database.

Yang Y, Wang F, Tong W, Lu X, Zhao F, Fang S, Wang S

Open source

DOI
10.3389/fonc.2026.1689130
Published
2026
Container
Frontiers in oncology
Publisher
Not recorded
Open access
yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fonc.2026.1689130,
  title = {Safety profile of ipilimumab in elderly patients: a disproportionate analysis based on the FDA Adverse Event Reporting System database.},
  author = {Yang Y and Wang F and Tong W and Lu X and Zhao F and Fang S and Wang S},
  year = {2026},
  journal = {Frontiers in oncology},
  doi = {10.3389/fonc.2026.1689130},
  url = {https://doi.org/10.3389/fonc.2026.1689130}
}

RIS

TY  - JOUR
TI  - Safety profile of ipilimumab in elderly patients: a disproportionate analysis based on the FDA Adverse Event Reporting System database.
AU  - Yang Y
AU  - Wang F
AU  - Tong W
AU  - Lu X
AU  - Zhao F
AU  - Fang S
AU  - Wang S
PY  - 2026
JO  - Frontiers in oncology
DO  - 10.3389/fonc.2026.1689130
UR  - https://doi.org/10.3389/fonc.2026.1689130
ER  - 

APA

Y, Y., F, W., W, T., X, L., F, Z., S, F., & S, W. (2026). Safety profile of ipilimumab in elderly patients: a disproportionate analysis based on the FDA Adverse Event Reporting System database.. Frontiers in oncology. https://doi.org/10.3389/fonc.2026.1689130

Source records